ArticleLasers in medical science2025
Resonant recognition model-guided biophysical insights into POMC, leptin, adiponectin, BDNF, insulin, irisin, GDF-15 interactions & executing PBMT targeting leptin/BDNF circuit to attenuate obesity.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity poses a major health concern. Synthetic compounds offer potential but come with adverse effects. Earlier Photo-Bio-Modulation (PBM) research was hindered by unclear parameter selection, notably in wavelength choice. The Resonant Recognition Model (RRM) proposes targeting specific protein-receptor pairs to activate anti-obesity mechanisms. The experiment aims to generate precise wavelengths using the RRM, simulated in MATLAB 2022b. It combines LED and LASER technologies targeting desired proteins through specific anatomical areas. An obese mouse model was induced via Monosodium L-glutamate (MSG) injections followed by a high-fat diet (HFD) with varied dietary conditions. Wavelengths for POMC, BDNF, Adiponectin, Insulin, Irisin, GDF-15, and Leptin were measured, where Leptin and BDNF pathways were validated experimentally using LED arrays (650-750 nm, 1.12mW and 500-535 nm, 1.12mW) and a laser (532 nm, < 500mW) over 10 days, with continuous monitoring of body weight and food intake. Treatment groups showed significant improvements in lipid profile, liver enzymes, inflammatory markers, and heightened SOD activity. This claimed anti-obesity potential and reversed leptin resistance through the restored leptin and BDNF-leptin circuit activity. The study's success in mitigating obesity within 10 days, sans apparent side effects, sets a precedent for disease and protein-specific wavelength selection. Clinical trial number Not applicable.
Indexed as
Identifiers
40536578What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.